Post Op Positive Seminal Vesicle Case 4: Prostate_4

Slides:



Advertisements
Similar presentations
Memorial Sloan-Kettering Cancer Center
Advertisements

NPCA data collection on men undergoing radical surgery for prostate cancer Paul Cathcart, NPCA Urology Project Coordinator.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
THE CLINICO-PATHOLOGIC PATTERNS OF PROSTATIC DISEASES AND PROSTATE CANCER IN SAUDI PATIENTS Hisham A. M. Mosli, FRCSC, FACS Taha A. Abdel-Meguid, MD Jaudah.
Coding Pitfalls Jessica K. Dohler, BS, CTR. Objectives 0 Know how to code the Tumor/Ext Eval code when using intraoperative findings 0 Know when to code.
Stephen Ko, M.D. Mayo Clinic Jacksonville
CA of Prostate:Incidence In a 50 y/o man In a 50 y/o man In autopsy: 40% In autopsy: 40% Clinical: 10% Clinical: 10% Death: 3% Death: 3% Most common non-cutanous.
Grade 1 (almost) never assigned Grade 2 rarely assigned on TURP and RP (exceptionally rare on biopsy)
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Radical Prostatectomy: A Critical Analysis of Surgical Quality Between the Open and Laparoscopic Approaches. Karim Touijer, MD.
Mr Jonathan Lewin MBBS, MRCS, MD, FRCS(Urol), FRACS Consultant Uro-Oncological Surgeon.
Radical Prostatectomy Sept 2009 till Aug 2010 South Mersey Cancer Network Manal Kumar Consultant Urologist.
PROSTATE CANCER EXPECTED MANAGEMENT & CURATIVE TREATMENT Dr. Abdullah A. Ghazi (R5) KSMC.
Is there a role for adjuvant/neoadjuvant chemotherapy in High risk prostate cancer? Giuseppe Procopio Fondazione IRCCS Istituto Nazionale Tumori Milano.
Steven Joniau Filip Ameye
Prostate Radiotherapy A-Z
National Program of Cancer Registries Education and Training Series How to Collect High Quality Cancer Surveillance Data.
Treatment options for locally recurrent Prostate Cancer Giuseppe Simone Mediterranean School of Oncology Roma
Prostate cancer: To screen or not to screen – To treat or not to treat Dr Oliver Klein – Medical Oncologist.
Modern Management of Prostate Cancer With Active Surveillance PROSTATE CANCER SYMPOSIUM NORTHWESTERN UNIVERSITY FEINBERG SCHOOL OF MEDICINE SEPTEMBER 10,
Directly Coded Summary Stage Prostate Cancer National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention and Control,
A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
NYU Medical Grand Rounds Clinical Vignette Josie Ni, PGY-3 9/13/11 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Prostate Pathology Emad Raddaoui, MD, FCAP, FASC.
Prostate Cancer Treatment: What’s Best For You?
CASE 1 65-year-old man No other diseases or previous surgeries July 2005: PSA 11.5 ng/ml; F/T: 9% After prostate biopsy revealing adenocarcinoma: RETROPUBIC.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.
Prostate Pathology. Prostate weighs 20 grams in normal adult Retroperitoneal organ,encircling the neck of bladder and urethra Devoid of a distinct capsule.
بسم الله الرحمن الرحيم. The role of three dimensional transrectal ultrasonography (3-D TRUS) and power Doppler sonography in prostatic lesions evaluation.
TNM Staging: Prostate TONYA BRANDENBURG, MHA, CTR KENTUCKY CANCER REGISTRY.
PSBIN caTissue Suite and caB2B 04/09/2012 Baris Suzek Andy Helsley Suhas Khot Dave Mulvihill.
Postsurgical Risk Factors for Prostate Cancer Mortality Slideset on: Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer–specific mortality.
NPCR Data Completeness and Quality Audits Review of: Collaborative Stage and Surgery Data Mary Lewis, CTR NPCR Program Consultant.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital.
International Neurourology Journal 2015;19:
Philipp Dahm, Ari D. Silverstein, Alon Z
Surgical Treatment in Locally Advanced Prostate Cancer
Professor Guram Karazanashvili MD, KMSc, DMSc MMT Hospital
Bladder Cancer and Prostatic Cancer
J. Edson PontesM.D. Professor Urologic Oncology WSU/KCI
Prostate Cancer Dr .Gehan Mohamed.
Radical Prostatectomy in pN+ Prostate Cancer
Post Op Positive Apex Margins Case 3: Prostate_3
Nat. Rev. Urol. doi: /nrurol
Decipher Prostate, Decipher Bladder and Decipher GRID
New Tracers for Prostate Cancer Imaging
RELAZIONE TRA “STAGE MIGRATION” E
Laparoscopic Radical prostatectomy: Is it still a treament of choice?
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Prostate Cancer: Highlights from 2006
Volume 49, Issue 2, Pages (February 2006)
Volume 51, Issue 6, Pages (June 2007)
Jaden D. Evans, MD, Krishan R
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Apollo Gleneagles Hospitals,
Volume 62, Issue 2, Pages (August 2012)
Volume 199, Issue 6, Pages (June 2018)
Pitfalls of Pathologic Staging in Prostate Cancer
What is New in Hormone Therapy for Prostate Cancer in 2007?
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.
Development and External Validation of Nomograms To Predict Adverse Pathological Characteristics After Robotic Prostatectomy: Results of a Prospective,
Patients who have received chemotherapy (n=60)
Disease-specific survival
Fernando P. Secin, Fernando J. Bianco, Nicholas T
Surgery for high-risk prostate cancer: The results of first 80 cases
Presentation transcript:

Post Op Positive Seminal Vesicle Case 4: Prostate_4 A 68-year-old gentleman with a preop clinical T2a, Gleason 8 (4+4) PSA 15 adenocarcinoma of the prostate. He is status post radical retro pubic prostatectomy and found to have pathologic T3b, pN0 (12 lymph nodes taken – all negative) Gleason Scores 8 (4+4) disease. Pathology reveals extracapsular extension at the right base and right seminal vesicle invasion. Surgical margins are negative. His PSA is undetectable and he is referred to you 90 days postop. He has recovered urinary continence but is now impotent. Please draw the CTV-TB for this case. www.rtog.org www.rtog.org

end